Skip to main content
Premium Trial:

Request an Annual Quote

Strategic Diagnostics to Offer High-Throughput Antibody Production

NEW YORK, March 1 (GenomeWeb News) - Strategic Diagnostics said today that it will offer a new high-throughput antibody reagent production service for customers in the proteomics, pharmaceutical, diagnostics, and biomedical research industries.


The technology, based on a process called genetic immunization, will allow Strategic Diagnostics to manufacture custom antibodies in high throughput based on specific genetic sequences provided by the customer, the company said.


Strategic Diagnostics, which is based in Newark, Del., also said that it has opened a research facility in Dallas dedicated to the new service, and has hired two new scientists to oversee the initiative: Ross Chambers and David Fancy, who join the company from the University of Texas, Southwestern Medical Center. Chambers and Fancy are widely recognized for their work in genetic immunization, Strategic Diagnostics said.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.